Creatine dilution (D3‐cr) is a technique for estimating total skeletal muscle mass (SMM) with practical utility, but has not been applied in athletic populations where body composition may differ to that in the normal population. This study aimed to assess the agreement between SMM derived from both D3‐cr and that obtained from whole‐body magnetic resonance imaging (MRI) in 15 male and 5 female national level kayakers (stature: 182.0 ± 13.1 and 170.0 ± 9.0 cm; body mass: 80.6 ± 9.9 and 66.4 ± 6.0 kg; V̇O2peak: 56.5 ± 7.0 and 49.6 ± 4.4 mL kg−1 min−1, mean ± SD). SMM was determined following 60 mg of dosed D3‐cr and analysis of expelled urine collected on four subsequent days for creatine, creatinine, D3‐cr, and D3‐creatinine using liquid chromatography/mass spectroscopy. SMM was then estimated by assuming a creatine pool size of 4.3 g/kg. During the same time period, a whole‐body MRI was undertaken to derive SMM from the analysis of multiple slices taken across the body. A strong positive correlation (F = 74.32; R = 0.90; P < .0001) between the two methods was observed, but the D3‐cr SMM was found to be significantly higher (43.3 ± 6.8 kg) when compared with MRI (36.3 ± 5.8 kg, P < .0001). However, the difference between the methods was removed when a higher intramuscular creatine pool (5.1 g/kg) was assumed. These data show that D3‐cr has potential utility in athletes, as referenced against MRI, but show that assumptions regarding creatine pool size need to be carefully considered.
The rapid expansion of commercial human spaceflight is forcing a re-examination of how we decide who is “fit to fly” in space. For more than six decades, astronaut selection has been dominated by government programmes employing stringent medical and psychological criteria designed to minimise risk for small cohorts undertaking long-duration, high-consequence missions. Contemporary standards such as NASA-STD-3001 reflect this paradigm, treating astronauts as highly trained national assets expected to perform reliably under extreme physiological and psychological stress. In contrast, commercial operators aim to fly large numbers of spaceflight participants with highly heterogeneous medical and psychological profiles, within regulatory frameworks that emphasise informed consent and currently impose very limited prescriptive health requirements on passengers. This review examines the evolution and structure of traditional astronaut selection, outlines emerging approaches to screening and certifying commercial spaceflight customers, and explores the conceptual and practical gap between “selection” and “screening”. Particular attention is given to the increasing relevance of behavioural and psychological risk in short-duration but high-stress commercial missions, where acute responses, passenger–crew interaction, and behavioural variability can influence safety, especially in mixed-capability crews. Drawing on agency standards, psychological selection research, and recent proposals for commercial medical guidelines, this paper proposes a risk-informed, mission- and role-specific framework that adapts lessons from government astronaut corps to the needs of commercial spaceflight. We argue that future practice must balance safety, inclusion, and commercial viability through proportionate, evidence-based risk management, supported by systematic data collection across government and commercial flights.
The rapid expansion of commercial human spaceflight is forcing a re-examination of how we decide who is “fit to fly” in space. For six decades, astronaut selection has been dominated by national space agencies using stringent, mission-driven criteria grounded in risk minimisation and long-duration operational demands. Contemporary standards such as NASA-STD-3001 and agency-specific medical regulations embed a philosophy in which astronauts are rare, heavily trained national assets expected to tolerate extreme environments with minimal performance degradation. In contrast, commercial operators aim to fly large numbers of spaceflight participants (SFPs) with highly heterogeneous medical and psychological profiles, under a US regulatory regime that emphasises informed consent and currently imposes very limited prescriptive health requirements on passengers. This article reviews the evolution and structure of traditional astronaut selection, outlines emerging approaches to screening and certify-ing commercial spaceflight customers, and explores the conceptual and practical gap between “selection” and “screening”. Drawing on agency standards, psychological se-lection research, and recent proposals for commercial medical guidelines, it proposes a risk-informed, mission-specific framework that adapts lessons from government as-tronaut corps to the needs of commercial spaceflight. We argue that future practice must balance inclusion and market growth with transparent, evidence-based risk manage-ment, supported by systematic data collection across government and commercial flights.